Serenatis Bio
Cambridge, GB · 2 known investors
Find your way into Serenatis Bio
402 people in our graph share verified history with the Serenatis Bio team — schools, employers, funds. One of them is your warm intro.
Kevin Johnsonunlockedknows David Cavalla · together at University of Cambridge (overlapped)
knows the team · via University of Cambridge
×3knows the team · via AstraZeneca
×7knows the team · via City University
Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options. The company's pipeline includes three novel candidates designed to work faster and with fewer side effects than existing medications.
Founders & leadership
NS
Nick SireauinExecutive Chairman & Co-founderNick Sireau is co-founder and executive chairman of Serenatis Bio, a Cambridge-based biotech developing small-molecule treatments for obsessive-compulsive disorder and other compulsive disorders. He previously led drug development efforts at the AKU Society, bringing nitisinone through clinical trials for alkaptonuria, and co-founded Orchard OCD, a non-profit organization focused on OCD research.
DC
David CavallainCEO & Co-founderHe has held executive roles in biotechnology and pharmaceuticals, authored a book on preclinical R&D strategy, and has published over 70 papers and patents in pharmaceutical development and strategy.
Investors · 2
Companies House · registry record
View on Companies House ↗- Registered name
- SERENATIS BIO LIMITED
- Company number
- 15944501
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 9 Sept 2024
- Registered office
- 66 Devonshire Road, Cambridge, CB1 2BL
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 30 Sept 2025 · next due 30 Jun 2027
- Confirmation statement
- last made up to 8 Sept 2025 · next due 22 Sept 2026
Current officers · 4
- David John Cavalla — director, appointed 9 Sept 2024
- Natalie Pankova — director, appointed 9 May 2025
- Nicolas Thierry Sireau — director, appointed 9 Sept 2024
- Susanne Stuffers — director, appointed 9 May 2025
Source: Companies House public register · retrieved 5 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Serenatis Bio do?
- Serenatis Bio develops small-molecule drugs targeting glutamate and dopamine pathways to treat obsessive-compulsive disorder, a mental health condition with limited effective therapeutic options. The company's pipeline includes three novel candidates designed to work faster and with fewer side effects than existing medications.
- Who founded Serenatis Bio?
- Serenatis Bio was founded by Nick Sireau, David Cavalla.
- Who are Serenatis Bio's investors?
- Serenatis Bio's investors include P53 Invest, Zinc.
- Where is Serenatis Bio headquartered?
- Serenatis Bio is headquartered in Cambridge, GB.